# Testing Nivolumab as a Potential Targeted Treatment in Cancers With Mismatch Repair Deficiency (MATCH-Subprotocol Z1D)

> **NCT04439214** · PHASE2 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 47 (actual)

## Conditions studied

- Advanced Lymphoma
- Advanced Malignant Solid Neoplasm
- Hematopoietic and Lymphoid Cell Neoplasm
- Refractory Lymphoma
- Refractory Malignant Solid Neoplasm
- Refractory Plasma Cell Myeloma

## Interventions

- **BIOLOGICAL:** Nivolumab

## Key facts

- **NCT ID:** NCT04439214
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-05-31
- **Primary completion:** 2018-10-11
- **Final completion:** 2020-05-17
- **Target enrollment:** 47 (ACTUAL)
- **Last updated:** 2021-04-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04439214

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04439214, "Testing Nivolumab as a Potential Targeted Treatment in Cancers With Mismatch Repair Deficiency (MATCH-Subprotocol Z1D)". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT04439214. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*